Nov 14, 2023 / 10:30AM GMT
Kelly Shi Jefferies LLC.-Analyst
Okay. Shall we start? Okay, great. Good morning, everyone. Thank you for attending Jefferies London Healthcare Conference. My name is Kelly Shi, one of the biotech analysts here. Please join me and welcome Mr. Raj Kannan, CEO, and Dr. John Hayslip, CMO of I-Mab Biopharma for this fireside chat session. Welcome both.
Questions and Answers:
Kelly Shi Jefferies LLC.-AnalystMaybe to start off, can you talk about for the past several months, after you got on board, Raj, what has been your focus, what has kept you busy? And what is your plan for the next 12 months?
Raj Kannan I-Mab-CEO
So first and foremost, Kelly, thank you for giving us the opportunity to present our investment thesis at this investment conference.
I think I've been onboard for four months right now. And the first and foremost was the science, really, to look at the portfolio. And so there's been a lot of work within the company to be able to focus on what's the